In particular, a therapeutic DNA vaccine must be able to generate both a CD8+ response, which directly kills infected or tumor cells, and a CD4+ helper response, which is able to increase and maintain the cytolytic response [50]. This evidence concerns the gene CD8A and neoplasm.